Bristol-Myers Squibb Co(NYSE:BMY) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Jul 28, 2016. Company reported revenue of $4.87B. Analysts estimated a revenue of $4.61B. Earnings per share were $0.69. Analysts had estimated an EPS of $0.66.
In a different note, On Jul 14, 2016, Jefferies said it Maintains its rating on Bristol-Myers Squibb Co. In the research note, the firm Raises the price-target to $77.00 per share. The shares have been rated ‘Hold’ by the firm. On Jun 14, 2016, Jefferies said it Maintains its rating on Bristol-Myers Squibb Co. In the research note, the firm Raises the price-target to $76.00 per share. The shares have been rated ‘Hold’ by the firm. On May 9, 2016, Credit Suisse said it Maintains its rating on Bristol-Myers Squibb Co. In the research note, the firm Raises the price-target to $75.00 per share. The shares have been rated ‘Outperform’ by the firm.
Bristol-Myers Squibb Co (BMY) made into the market gainers list on Thursdays trading session with the shares advancing 0.70% or 0.52 points. Due to strong positive momentum, the stock ended at $75.32, which is also near the day’s high of $75.62. The stock began the session at $74.96 and the volume stood at 34,74,924 shares. The 52-week high of the shares is $77.12 and the 52 week low is $51.82. The company has a current market capitalization of $125,849 M and it has 1,67,08,58,500 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Jul 11, 2016, Lamberto Andreotti (director) sold 23,200 shares at $74.65 per share price.Also, On Jun 16, 2016, John E Elicker (SVP, Public Affairs & IR) sold 11,820 shares at $72.69 per share price.On May 24, 2016, Charles A Bancroft (EVP & Chief Financial Officer) sold 30,201 shares at $70.79 per share price, according to the Form-4 filing with the securities and exchange commission.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.